Loading organizations...
§ Private Profile · 20 Overland St. Boston, MA 02215
AI Proteins is a company.
AI Proteins has raised $59.5M across 2 funding rounds.
Key people at AI Proteins.
AI Proteins has raised $59.5M in total across 2 funding rounds.
AI Proteins designs a new class of de novo miniprotein medicines, engineering entirely new protein therapeutics from the ground up. The company leverages a unique combination of artificial intelligence, robotics, and synthetic biology to create programmable, safer, and highly precise biologic drugs. Their platform allows for the bespoke construction of miniproteins, which aim to address therapeutic challenges with novel molecular architectures.
Chris Bahl serves as the founder, President, CEO, and Chief Scientific Officer of AI Proteins. He established the company based on his work as a founding faculty member at the Institute for Protein Design, driven by the profound insight that AI could fundamentally transform the creation of novel protein-based drugs. This conviction led him to transition from his academic research to spearhead the biotech startup.
The company develops a pipeline of AI-designed miniprotein medicines applicable across various therapeutic areas, including immune engagers, metabolic conditions, and radioligand therapies. AI Proteins envisions engineering the future of biologics by advancing AI-driven molecular design. Their long-term mission centers on providing innovative and effective therapeutic solutions through the precise and efficient creation of novel protein structures.
Key people at AI Proteins.
AI Proteins is a Boston-based biotech company that designs entirely new de novo miniproteins using AI, synthetic biology, and robotics for drug discovery and therapeutics.[2][3][5] It targets conditions like inflammation, metabolic diseases, and cancer by creating synthetic proteins optimized for oral delivery, high specificity, stability, and low cost, serving pharmaceutical clients and advancing internal programs.[1][3] The company solves the limitations of natural proteins—such as poor tissue penetration, immunogenicity, and evolutionary constraints—by engineering modular, purpose-built miniproteins from first principles, accelerating lead candidate generation at scale.[3][4][5] Recent momentum includes a $41.5M Series A in November 2025 and a Bristol Myers Squibb collaboration worth up to $400M, with in vivo proof-of-concept across 150+ targets.[3][4]
AI Proteins emerged from advances in generative AI and high-throughput platforms to re-imagine protein therapeutics, unconstrained by natural evolution.[2][3][5] While specific founders are not detailed in available sources, the company is headquartered in Boston and has quickly gained traction through its novel de novo design approach, validating scalability via internal programs and partnerships.[3][4] Pivotal moments include the December 2024 Bristol Myers Squibb research collaboration and option agreement, alongside achieving in vivo proof-of-concept for multiple molecules, culminating in the $41.5M Series A led by Mission BioCapital and Santé Ventures in November 2025.[3][4]
AI Proteins rides the convergence of generative AI, synthetic biology, and automation in biotech, enabling a new class of programmable therapeutics amid rising demand for precise, scalable biologics.[3][5] Timing is ideal post-2024 AI breakthroughs, as high-throughput platforms address biotech's productivity crisis—traditional proteins face immunogenicity and manufacturing hurdles, while miniproteins offer safer, cheaper alternatives.[1][4] Market forces like pharma's push for novel modalities (e.g., multispecifics) and partnerships like Bristol Myers Squibb favor it, influencing the ecosystem by unlocking de novo design for non-therapeutic fields and setting a scalable blueprint for AI-driven drug discovery.[3][4]
AI Proteins is positioned to pioneer de novo miniproteins as the next therapeutic frontier, with Series A funds advancing clinical candidates and the BMS deal potentially yielding milestones up to $400M.[3][4] Trends like AI model refinement from proprietary data, robotics scaling, and hub-and-spoke expansion will accelerate multi-program progress across therapeutics, diagnostics, and agriculture.[4][5] Its influence may evolve by commoditizing protein design, powering pharma pipelines and spinouts, ultimately delivering oral, patient-tuned biologics that redefine biotech efficiency—transforming "artisanal science" into industrial precision.[3]
AI Proteins has raised $59.5M across 2 funding rounds. Most recently, it raised $41.5M Series A in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 19, 2025 | $41.5M Series A | Steven Tregay, Omar H. Khalil | Cobro Ventures, Lightchain Capital | Announced |
| Jan 1, 2022 | $18M Seed | Cobro Ventures, Drew Dennison | — | Announced |
AI Proteins has raised $59.5M in total across 2 funding rounds.
AI Proteins's investors include Steven Tregay, Omar H. Khalil, Cobro Ventures, Lightchain Capital, Drew Dennison.
